Medicare Part D Beneficiaries With Myeloma Receive Novel Therapies More Frequently, Have Better Survival...
People with myeloma who have prescription drug coverage under Medicare are less likely to use older cytotoxic chemotherapy and more likely to receive newly...
U.K. Panel Rejects Venetoclax-Rituximab Combo for CLL
The U.K.’s National Institute for Health and Care Excellence (NICE) has published draft guidance rejecting the combination of venetoclax and rituximab for the treatment...
FDA Approves New Treatment for Hemophilia
The U.S. Food and Drug Administration (FDA) approved BAY94-9027, or antihemophilic factor (recombinant), PEGylated-aucl, for the prophylactic treatment of adults and adolescents (≥12 years)...
Evaluating Twice-Yearly Denosumab for Transfusion-Dependent, Thalassemia-Induced Osteoporosis
Treatment with twice-yearly denosumab improved spinal bone mineral density (BMD) compared with placebo in patients with transfusion-dependent thalassemia (TDT)–induced osteoporosis, according to results of...
Pre-emptive Rituximab Prevents Long-Term Relapses in Immune-Mediated TTP
Patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who have persistent, severe ADAMTS13 deficiency have a high likelihood of relapse, but pre-emptive treatment with rituximab...
Higher Childhood Leukemia Risk in Offspring Raises Questions About Hormonal Contraceptive Safety
Children born to women who were using hormonal contraception within three months of pregnancy and during pregnancy have a higher risk of developing myeloid...
MRD Negativity Measured Via Next-Generation Sequencing Predicts Long-Term Survival in Myeloma
Measuring minimal residual disease (MRD) status using next-generation sequencing (NGS) represented a prognostic biomarker for survival in patients with multiple myeloma (MM), according to...
Post-Transplant Gene Mutations Predict Risk for MDS Progression
Sequencing bone marrow samples early after patients with myelodysplastic syndromes (MDS) have undergone allogeneic hematopoietic cell transplantation (AHCT) could help identify patients who are...
How I Treat In Brief: Managing Ibrutinib-Refractory Chronic Lymphocytic Leukemia
Jennifer A. Woyach, MD, associate professor at the Ohio State University Comprehensive Cancer Center, wrote about her strategy for the management of patients with...
How to Treat Anemia in a Patient Who Refuses Transfusions for Religious Reasons
This month, Neil A. Zakai, MD, discusses how to treat anemia in a patient who refuses packed red blood cells.
And don't forget to check out...
Current Issue
November 2018, Volume 4, Issue 13
This issue features a look at the U.S. drug pricing system, attempts to solve physician burnout, and more.
